ORIC Pharmaceuticals Q2 2026 net loss widens to $41.5 million; cash $387.6 million
ORIC Pharmaceuticals reported a second-quarter 2026 net loss of $41.5 million, up from $36.4 million a year earlier, as research and development spending rose. Loss per share narrowed to $0.38 from $0.47, but the filing shows a higher weighted-average share count, and the company said cash and investments of $387.6 million, including $59.9 million raised under its at-the-market program, fund operations into the second half of 2028.
Key points
- Net loss was $41.5 million for the quarter ended June 30, 2026, versus $36.4 million a year earlier; loss per share was $0.38 versus $0.47.
- R&D expenses rose to $36.3 million from $30.5 million, mainly due to external costs for rinzimetostat.
- Cash, cash equivalents and investments totaled $387.6 million as of June 30, 2026, which the company expects to fund its operating plan into the second half of 2028.
- The Himalayas-1 global Phase 3 trial of rinzimetostat was initiated, and a supply agreement with Bayer provides darolutamide for the trial at no cost.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.